[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Immunotherapy 101 for Multiple Myeloma Patients

Immunotherapy 101 for Multiple Myeloma Patients image

Immunotherapy 101 for Multiple Myeloma Patients

Webinar
event Nov 15, 2022 / 01:00PM - 02:00PM EST
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Myeloma expert Dr. Malin Hultcrantz is back due to popular demand. This time she shares with us a crash course in Immunotherapy. What makes immunotherapy different? Will it "take over" chemotherapy? Is it available for newly diagnosed patients? Learn answers to these questions and come with your own. We're looking forward to it!

 

Schedule & Agenda

The panelist Audrey Burton-Bethke
01:00 PM
Introduction
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Malin Hultcrantz.

The panelist Malin Hultcrantz, MD, PhD
01:05 PM
Presentation
Malin Hultcrantz, MD, PhD

Dr. Malin Hultcrantz shares with us a crash course in Immunotherapy.

 

Event panelist Audience
01:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD

Malin Hultcrantz, MD, PhD, is a board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders including the precursor disorders monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma at the Memorial Sloan Kettering Cancer Center. She is focused on further optimizing treatment strategies for people with multiple myeloma, and offers a variety of modern treatments including clinic trials and novel immunotherapies. She is also working on measures to continue to improve patients’ quality of life while receiving treatment for multiple myeloma. Additionally, she has a particular interest in studying mechanisms and markers of progression from precursor disease to multiple myeloma. As part of this effort, she is working with her colleagues to develop targeted genomic tests for disease characterization and measurement of minimal residual disease. Better understanding of disease biology allows for better risk stratification and personalized treatment including early treatment for patients with high-risk precursor disease. In 2015, Dr. Hultcrantz received the Research Fellow Award, Multiple Myeloma Research Foundation and the International Postdoc Award, Swedish Research Council. Dr. Hultcrantz is fluent in Swedish and English.

Read Bio
The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Treatment & Testing group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.